TibaRay says its cancer technology now spans 21 patents and $30 million raised

TibaRay says its Galactica radiotherapy platform is moving toward broader commercial use as the company builds a patent portfolio, secures funding and starts initial manufacturing with partner Leo Cancer Care. The milestone underscores how Stanford-born research is advancing toward clinical deployment in a market seeking faster, more precise cancer treatment.

Why it matters: - TibaRay is trying to turn a Stanford-born cancer technology into a commercial radiotherapy platform with broader clinical use. - The company says faster treatment and less damage to healthy tissue are the main patient-care goals behind Galactica. - More efficient cancer therapy matters to hospital systems looking for alternatives to legacy equipment.

What happened: - TibaRay said its cancer technology is now covered by 21 issued and pending patents. - The portfolio includes exclusively licensed Stanford/SLAC technology and TibaRay-owned intellectual property. - The company said it has raised more than $30 million to date, including $13 million in non-dilutive grants. - TibaRay said it has begun initial manufacturing of the first phase of Galactica systems for integration with partner Leo Cancer Care. - The company described that manufacturing step as an early move toward commercialization.

The details: - Galactica is TibaRay’s proprietary linear accelerator platform. - The platform is designed to deliver radiotherapy faster and with greater precision than legacy equipment. - Leo Cancer Care’s Grace system is designed as an upright radiotherapy platform that treats patients sitting or standing rather than lying down. - The Grace system is intended to shorten treatment sessions and improve comfort. - The platform is smaller than current systems on the market. - The platform also supports FLASH, an emerging approach that delivers radiation in a fraction of a second. - Cancer radiotherapy and radiobiology experts believe FLASH may reduce damage to surrounding healthy tissue. - TibaRay is headquartered in Fremont, California. - The company says its technology is advancing radiotherapy and other commercial applications.

Between the lines: - The patent estate and funding level suggest TibaRay is shifting from research validation toward commercialization. - The Leo Cancer Care partnership gives the company a route into system integration and potential market adoption. - The emphasis on upright treatment, smaller hardware and FLASH points to a push against the limits of current radiotherapy systems. - TibaRay’s messaging frames the company as a bridge from academic research to patient care, not just a device developer.

What's next: - TibaRay will continue moving Galactica through manufacturing and toward clinical deployment. - The company is also pursuing broader commercial applications beyond cancer care. - Interested investors can review the current investment opportunity at TibaRay’s Wefunder campaign. - TibaRay says its longer-term mission is Curing Cancer in a FLASH™.